Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607095 | 0.92 | LMNA (0.49) | MAPTPOLBMEN1KMT2ADRD2 | |
| SCHEMBL6512902 | 0.90 | ALDH1A1 (0.53) | ALDH1A1MAPTPOLBMEN1GAA | |
| SCHEMBL21623111 | 0.89 | HDAC1 (0.44) | MAPTPOLBTPSAB1TPSD1TPSG1 | |
| SCHEMBL6606914 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTPOLBGAATSHR | |
| SCHEMBL8359060 | 0.82 | MMP13 (0.43) | MAPT | |
| SCHEMBL6606492 | 0.81 | LMNA (0.52) | MAPTDRD2LMNATHRB | |
| SCHEMBL6517676 | 0.81 | MAPT (0.44) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL6605189 | 0.80 | MMP13 (0.60) | MAPTKMT2ALMNATHRB | |
| SCHEMBL21623110 | 0.80 | STAT3 (0.41) | MAPTPOLBDRD2 | |
| SCHEMBL6609494 | 0.80 | LMNA (0.51) | MAPTPOLBMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368327-B1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1368327-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | ALDH1A1 399/4885MAPT 4336/4885POLB 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.